Referências
Principais artigos
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Texto completo Resumo
Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Resumo
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Resumo
Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Resumo
Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Texto completo
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].Texto completo
Artigos de referência
1. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581-96. Resumo
2. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov;5(11):873-82. Resumo
3. Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol. 1999 May-Jun;17(3):279-89. Resumo
4. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev. 2001 Oct;14(4):659-88.Texto completo Resumo
5. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008 Mar;8(3):191-9. Resumo
6. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003 Feb;3(2):87-98. Resumo
7. World Health Organization. The post kala-azar dermal leishmaniasis (PKDL) atlas: a manual for health workers. 2012 [internet publication].Texto completo
8. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Texto completo Resumo
9. Cabello I, Caraballo A, Millan Y. Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002 Mar-Apr;44(2):105-7.Texto completo Resumo
10. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017 May 26;6:750.Texto completo Resumo
11. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:107-14. Resumo
12. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. Resumo
13. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop. 2008 Jan;105(1):1-9. Resumo
14. Global Health Data Exchange. Global burden of disease study 2019 (GBD 2019) data resources [internet publication].Texto completo
15. World Health Organization. Fact sheet: leishmaniasis. Mar 2020 [internet publication].Texto completo
16. World Health Organization. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014. Wkly Epidemiol Rec.2016:91:287-96.Texto completo
17. World Health Organization. Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic. Nov 2022 [internet publication].Texto completo
18. Pan American Health Organization. Leishmaniasis: epidemiological report of the Americas, No. 10 (December 2021). Dec 2021 [internet publication].Texto completo
19. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr;21(2):334-59.Texto completo Resumo
20. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 Jan;19(1):111-26.Texto completo Resumo
21. Wright NA, Davis LE, Aftergut KS, et al. Cutaneous leishmaniasis in Texas: A northern spread of endemic areas. J Am Acad Dermatol. 2008 Apr;58(4):650-2. Resumo
22. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004 Feb;53(2):158-66.Texto completo Resumo
23. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM. 2004 Dec;97(12):781-8. Resumo
24. Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004 Dec 1;39(11):1674-80.Texto completo Resumo
25. Pan American Health Organization. Leishmaniases. Epidemiological report of the Americas, December 2020. Dec 2020 [internet publication].Texto completo
26. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.Texto completo Resumo
27. World Health Organization. WHO responds to visceral leishmaniasis outbreak inKenya. Jun 2017 [internet publication].Texto completo
28. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec;22(12):552-7. Resumo
29. Myles O, Wortmann GW, Cummings JF, et al. Visceral leishmaniasis: clinical observations in 4 US army soldiers deployed to Afghanistan or Iraq, 2002-2004. Arch Intern Med. 2007 Sep 24;167(17):1899-901. Resumo
30. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis. 2002 Aug 1;35(3):261-7.Texto completo Resumo
31. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR. 2017 Feb;24(2):2-7. Resumo
32. Mody RM, Lakhal-Naouar I, Sherwood JE, et al. Asymptomatic visceral Leishmania infantum infection in US soldiers deployed to Iraq. Clin Infect Dis. 2019 May 30;68(12):2036-44.Texto completo Resumo
33. Duprey ZH, Steurer FJ, Rooney JA, et al. Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerg Infect Dis. 2006 Mar;12(3):440-6.Texto completo Resumo
34. Sereno D. Leishmania (Mundinia) spp.: from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect. 2019 Apr 4;30:100540.Texto completo Resumo
35. Leelayoova S, Siripattanapipong S, Manomat J, et al. Leishmaniasis in Thailand: a review of causative agents and situations. Am J Trop Med Hyg. 2017 Mar;96(3):534-42.Texto completo Resumo
36. Desbois N, Pratlong F, Quist D, et al. Leishmania (Leishmania) martiniquensis n. sp. (Kinetoplastida: Trypanosomatidae), description of the parasite responsible for cutaneous leishmaniasis in Martinique Island (French West Indies). Parasite. 2014;21:12.Texto completo Resumo
37. Depaquit J, Kaltenbach ML, Gay F. Visceral leishmaniasis in traveler to Guyana caused by Leishmania siamensis, London, UK. Emerg Infect Dis. 2018 Aug;24(8):1599-600.Texto completo Resumo
38. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75. Resumo
39. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun. 2002 Dec;70(12):6919-25.Texto completo Resumo
40. Weirather JL, Duggal P, Nascimento EL, et al. Comprehensive candidate gene analysis for symptomatic or asymptomatic outcomes of Leishmania infantum infection in Brazil. Ann Hum Genet. 2017 Jan;81(1):41-8.Texto completo Resumo
41. Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature. 2004 Jul 22;430(6998):463-7. Resumo
42. Vannier-Santos MA, Martiny A, de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des. 2002;8(4):297-318. Resumo
43. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2000 Nov;2(14):1765-73. Resumo
44. Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly? Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6704-9.Texto completo Resumo
45. Warburg A, Saraiva E, Lanzaro GC, et al. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc Lond B Biol Sci. 1994 Jul 29;345(1312):223-30. Resumo
46. Basu MK, Ray M. Macrophage and Leishmania: an unacceptable coexistence. Crit Rev Microbiol. 2005;31(3):145-54. Resumo
47. Kariyawasam KKGDUL, Selvapandiyan A, Siriwardana HVYD, et al. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies. Parasitology. 2018 Apr;145(4):443-52.Texto completo Resumo
48. Zhang WW, Ramasamy G, McCall LI, et al. Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog. 2014 Jul;10(7):e1004244.Texto completo Resumo
49. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis. 1987 Dec;156(6):1030-3. Resumo
50. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999 Aug;13(8):459-65. Resumo
51. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005 May;11(5):655-62.Texto completo Resumo
52. Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis. 2004 Sep;10(9):1681-4.Texto completo Resumo
53. Kolaczinski JH, Reithinger R, Worku DT, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008 Apr;37(2):344-52. Resumo
54. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):184-8.Texto completo Resumo
55. Pennisi MG, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors. 2015 Jun 4;8:302.Texto completo Resumo
56. Asfaram S, Fakhar M, Teshnizi SH. Is the cat an important reservoir host for visceral leishmaniasis? A systematic review with meta-analysis. J Venom Anim Toxins Incl Trop Dis. 2019 Jun 10;25:e20190012.Texto completo Resumo
57. Public Health England. HAIRS risk assessment: canine leishmaniosis. Jan 2022 [internet publication].Texto completo
58. World Veterinary Association. WVA policies: WVA position statement on Leishmaniosis. Apr 2021 [internet publication].Texto completo
59. Kopterides P, Mourtzoukou EG, Skopelitis E, et al. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1181-9. Resumo
60. Català A, Roé E, Dalmau J, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015;230(3):204-7.Texto completo Resumo
61. Arens K, Filippis C, Kleinfelder H, et al. Anti-tumor necrosis factor α therapeutics differentially affect Leishmania infection of human macrophages. Front Immunol. 2018 Jul 31;9:1772.Texto completo Resumo
62. World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. June 2022 [internet publication].Texto completo
63. Stockdale L, Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2278.Texto completo Resumo
64. Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr;11(4):322-5. Resumo
65. Romero GA, Boelaert M. Control of visceral leishmaniasis in Latin America: a systematic review. PLoS Negl Trop Dis. 2010 Jan 19;4(1):e584.Texto completo Resumo
66. González U, Pinart M, Sinclair D, et al, Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev. 2015 Aug 5;2015(8):CD008736.Texto completo Resumo
67. Picado A, Singh SP, Rijal S, et al. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010 Dec 29;341:c6760.Texto completo Resumo
68. Chowdhury R, Dotson E, Blackstock AJ, et al. Comparison of insecticide-treated nets and indoor residual spraying to control the vector of visceral leishmaniasis in Mymensingh District, Bangladesh. Am J Trop Med Hyg. 2011 May;84(5):662-7. Resumo
69. Costa CH. How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):232-42.Texto completo Resumo
70. Sousa-Paula LC, Silva LGD, Sales KGDS, et al. Failure of the dog culling strategy in controlling human visceral leishmaniasis in Brazil: a screening coverage issue? PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0007553.Texto completo Resumo
71. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis. 1991 Sep-Oct;13(5):1009-17. Resumo
72. Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017 May 12;11(5):e0005527.Texto completo Resumo
73. ClinicalTrials.gov. A study to assess the safety, efficacy and immunogenicity of leishmania vaccine ChAd63-KH in PKDL. Apr 2020 [internet publication].Texto completo
74. ClinicalTrials.gov. A study of a new leishmania vaccine candidate ChAd63-KH (Leish2a). Jan 2020 [internet publication].Texto completo
75. Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Mol Ther. 2021 Jul 7;29(7):2366-77.Texto completo Resumo
76. Boelaert M, Bhattacharya S, Chappuis F, et al. Evaluation of rapid diagnostic tests: visceral leishmaniasis. Nat Rev Microbiol. 2007;5(suppl):S30-9.
77. Escobar MA, Martinez F, Scott Smith D, et al. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop Doct. 1992;22 Suppl 1:69-78;63-4. Resumo
78. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007 Jan;45(1):21-5.Texto completo Resumo
79. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Resumo
80. Sevilha-Santos L, Dos Santos Júnior ACM, Medeiros-Silva V, et al. Accuracy of qPCR for quantifying Leishmania kDNA in different skin layers of patients with American tegumentary leishmaniasis. Clin Microbiol Infect. 2019 Feb;25(2):242-7.Texto completo Resumo
81. Cota GF, de Sousa MR, Demarqui FN, et al. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012;6(5):e1665.Texto completo Resumo
82. Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol. 2006 Jul;44(7):2343-7.Texto completo Resumo
83. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):673-5. Resumo
84. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006 Oct;75(4):739-43.Texto completo Resumo
85. Boelaert M, Rijal S, Regmi S, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg. 2004 Jan;70(1):72-7.Texto completo Resumo
86. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000 Oct;31(4):1093-5.Texto completo Resumo
87. Weigle KA, de Dávalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg. 1987 May;36(3):489-96. Resumo
88. Kager PA, Rees PH. Splenic aspiration. Review of the literature. Trop Geogr Med. 1983 Jun;35(2):111-24. Resumo
89. Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):505-7. Resumo
90. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2005 Jun;72(6):811-4. Resumo
91. Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev. 2002 Jul;15(3):374-89.Texto completo Resumo
92. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002 Sep;9(5):951-8.Texto completo Resumo
93. Maurya R, Singh RK, Kumar B, et al. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol. 2005 Jul;43(7):3038-41.Texto completo Resumo
94. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ. 2006 Oct 7;333(7571):723.Texto completo Resumo
95. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev. 2014 Jun 20;2014(6):CD009135.Texto completo Resumo
96. Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):32-40. Resumo
97. de Assis TS, Braga AS, Pedras MJ, et al. Multi-centric prospective evaluation of rk39 rapid test and direct agglutination test for the diagnosis of visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):81-5. Resumo
98. Harith AE, Kolk AH, Kager PA, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg. 1987;81(4):603-6. Resumo
99. Iqbal J, Hira PR, Saroj G, et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol. 2002 Feb;40(2):475-9.Texto completo Resumo
100. Marty P, Lelièvre A, Quaranta JF, et al. Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):690-1. Resumo
101. Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007 Jan;5(1):24-9. Resumo
102. World Health Organization. WHO Guidelines for malaria. Jun 2022 [internet publication].Texto completo
103. Gryseels B, Polman K, Clerinx J, et al. Human schistosomiasis. Lancet. 2006 Sep 23;368(9541):1106-18. Resumo
104. Schaefer KU, Kurtzhals JA, Gachihi GS, et al. A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg. 1995 Sep-Oct;89(5):471-5. Resumo
105. Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect. 1995 Apr;114(2):297-318.Texto completo Resumo
106. Cardo LJ. Leishmania: risk to the blood supply. Transfusion. 2006 Sep;46(9):1641-5. Resumo
107. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Resumo
108. Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, et al. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713.Texto completo Resumo
109. Dereure J, Duong Thanh H, Lavabre-Bertrand T, et al. Visceral leishmaniasis: persistence of parasites in lymph nodes after clinical cure. J Infect. 2003 Jul;47(1):77-81. Resumo
110. Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999 Jan;28(1):49-51.Texto completo Resumo
111. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 998;76(1):25-32.Texto completo Resumo
112. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006 Oct 1;43(7):917-24.Texto completo Resumo
113. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005 Dec;5(12):763-74. Resumo
114. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 1;38(3):377-83.Texto completo Resumo
115. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000 Feb;13(4):243-8. Resumo
116. Carnielli JBT, Crouch K, Forrester S, et al. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. EBioMedicine. 2018 Oct;36:83-91.Texto completo Resumo
117. Tiwary P, Kumar D, Sundar S. Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis. Am J Trop Med Hyg. 2018 Feb;98(2):492-6.Texto completo Resumo
118. Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother. 2006 Oct;58(4):811-5.Texto completo Resumo
119. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother. 2005 Feb;55(2):229-33.Texto completo Resumo
120. Pekelharing JE, Gatluak F, Harrison T, et al. Outcomes of visceral leishmaniasis in pregnancy: a retrospective cohort study from South Sudan. PLoS Negl Trop Dis. 2020 Jan;14(1):e0007992.Texto completo Resumo
121. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010 Dec;7(12):4267-77.Texto completo Resumo
122. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001 Nov;6(11):849-54.Texto completo Resumo
123. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8(4):319-42. Resumo
124. Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007 Aug;77(2):266-74. Resumo
125. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica. 2011 May;118(2):87-96. Resumo
126. Heras-Mosteiro J, Monge-Maillo B, Pinart M, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067.Texto completo Resumo
127. Pinart M, Rueda JR, Romero GA, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834.Texto completo Resumo
128. Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis. 2013 Aug;57(3):370-80.Texto completo Resumo
129. López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, et al. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016 Jul 26;16:360.Texto completo Resumo
130. Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. 2015 May 26;10(5):e0122569.Texto completo Resumo
131. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. Resumo
132. Sosa N, Pascale JM, Jiménez AI, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253.Texto completo Resumo
133. Soto J, Soto P, Ajata A, et al. Topical 15% paromomycin-aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019 Feb 15;68(5):844-9.Texto completo Resumo
134. Kim DH, Chung HJ, Bleys J, et al. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis. 2009;3(2):e381.Texto completo Resumo
135. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017 Sep 19;12(9):e0184777.Texto completo Resumo
136. Soto J, Paz D, Rivero D, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg. 2016 Apr;94(4):852-6.Texto completo Resumo
137. Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One. 2017 Oct 9;12(10):e0186117.Texto completo Resumo
138. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Resumo
139. Roussel M, Nacher M, Frémont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2006 Jun;100(4):307-14. Resumo
140. Lai A Fat EJ, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol. 2002 Nov;41(11):796-800. Resumo
141. Christen JR, Bourreau E, Demar M, et al. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure. Travel Med Infect Dis. 2018 Jul - Aug;24:31-6. Resumo
142. Soto J, Soto P, Ajata A, et al. Miltefosine combined with intralesional pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia. Am J Trop Med Hyg. 2018 Nov;99(5):1153-5.Texto completo Resumo
143. Dorlo TP, Kager PA. Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis. 2008 May 28;2(5):e225.Texto completo Resumo
144. Machado PR, Rosa ME, Guimarães LH, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 2015 Sep 15;61(6):945-9.Texto completo Resumo
145. Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Texto completo
146. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007 Aug;46(8):848-52. Resumo
147. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis. 2007 Aug 15;45(4):478-82.Texto completo Resumo
148. Avila-García M, Mancilla-Ramírez J, Segura-Cervantes E, et al. Transplacental transmission of cutaneous Leishmania mexicana strain in BALB/c mice. Am J Trop Med Hyg. 2013 Aug;89(2):354-8.Texto completo Resumo
149. Pan American Health Organization. Manual of procedures for leishmaniases surveillance and control in the Americas. Dec 2019 [internet publication].Texto completo
150. Cunha MA, Leão AC, de Cassia Soler R, et al. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: a retrospective study. Am J Trop Med Hyg. 2015 Dec;93(6):1214-8.Texto completo Resumo
151. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis. 2007 Feb 1;44(3):350-6.Texto completo Resumo
152. Osman OF, Oskam L, Zijlstra EE, et al. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment. Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):397-400. Resumo
153. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11;362(6):504-12.Texto completo Resumo
154. Lucero E, Collin SM, Gomes S, et al. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis. 2015 Apr 2;9(4):e0003699.Texto completo Resumo
155. Goswami RP, Goswami RP, Das S, et al. Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome™). Am J Trop Med Hyg. 2016 Jan;94(1):93-8.Texto completo Resumo
156. Pandey K, Pal B, Siddiqui NA, et al. Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India. Am J Trop Med Hyg. 2017 Nov;97(5):1498-502.Texto completo Resumo
157. Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635.Texto completo Resumo
158. Goyal V, Mahajan R, Pandey K, et al. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830.Texto completo Resumo
159. Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015 Oct;28(5):426-37. Resumo
160. Gebreyohannes EA, Bhagvathula AS, Abegaz TM, et al. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018 Oct 19;7(1):108.Texto completo Resumo
161. Romero GAS, Costa DL, Costa CHN, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005706.Texto completo Resumo
162. Assis TSM, Rabello A, Cota G, et al. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272.Texto completo Resumo
163. Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme. Clin Drug Investig. 2017 Mar;37(3):259-72.Texto completo Resumo
164. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 5;377(9764):477-86. Resumo
165. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571-81.Texto completo Resumo
166. Jamil KM, Haque R, Rahman R, et al. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004118.Texto completo Resumo
167. Akuffo H, Costa C, van Griensven J, et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375.Texto completo Resumo
168. Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017 Jan;31(1). Resumo
169. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].Texto completo
170. World Health Organization. WHO technical report series 949: control of the leishmaniases - report of a meeting of the WHO Expert Committee on the control of leishmaniases. 2010 [internet publication].Texto completo
171. Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988.Texto completo Resumo
172. Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-Arm, phase 3 trial. Clin Infect Dis. 2022 Oct 12;75(8):1423-32.Texto completo Resumo
173. Cota GF, de Sousa MR, Fereguetti TO, et al. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis. 2013 May 2;7(5):e2195.Texto completo Resumo
174. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS. 1999 Jun 18;13(9):1063-9. Resumo
175. Delgado J, Macías J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999 Nov;61(5):766-9. Resumo
176. Diro E, Edwards T, Ritmeijer K, et al. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019 Feb 21;13(2):e0007132.Texto completo Resumo
177. Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018 Jan 18;66(3):444-51.Texto completo Resumo
178. Clemente W, Vidal E, Girão E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015 Jan;21(1):89-95.Texto completo Resumo
179. Pijpers J, den Boer ML, Essink DR, et al. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - a review and meta-analysis. PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173.Texto completo Resumo
180. World Health Organization. Statement on miltefosine - potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). Feb 2022 [internet publication].Texto completo
181. Basher A, Maruf S, Nath P, et al. Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh – a series of four cases. Am J Trop Med Hyg. 2017 Oct;97(4):1111-5.Texto completo Resumo
182. Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005 Sep;99(6):563-9. Resumo
183. Moulik S, Chaudhuri SJ, Sardar B, et al. Monitoring of parasite kinetics in Indian post-kala-azar dermal leishmaniasis. Clin Infect Dis. 2018 Jan 18;66(3):404-10.Texto completo Resumo
184. Ramesh V, Dixit KK, Sharma N, et al. Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis. J Infect Dis. 2020 Feb 3;221(4):608-17.Texto completo Resumo
185. World Health Organization. WHO technical report series 949: control of the leishmaniases – report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. 2010 [internet publication].Texto completo
186. World Health Organization. South Sudan intensifies measures against visceral leishmaniasis to improve health and social well-being of affected populations. Nov 2018 [internet publication].Texto completo
187. Drugs for Neglected Diseases initiative. Fexinidazole/miltefosine combination (VL). Aug 2016 [internet publication].Texto completo
188. Drugs for Neglected Diseases Initiative. DNDI-0690. Aug 2019 [internet publication].Texto completo
189. ClinicalTrials.gov. Single oral dose escalation study of DNDI-0690 in healthy male subjects. Apr 2019 [internet publication].Texto completo
190. Drugs for Neglected Diseases initiative. R&D portfolio update February 2019: DNDi Leishmaniasis programme. Feb 2019 [internet publication].Texto completo
191. ClinicalTrials.gov. Safety, tolerability and pharmacokinetics (PKs) investigation of GSK3186899 in healthy subjects. Apr 2020 [internet publication].Texto completo
192. Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018 Oct;31(4):.Texto completo Resumo
193. Drugs for Neglected Diseases initiatives. Annual report 2020: medicines for the people. 2020 [internet publication].Texto completo
194. Hossain MS, Kumar A, Hossain AFMA, et al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infect Dis Poverty. 2018 Aug 13;7(1):80.Texto completo Resumo
195. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006 Aug 1;43(3):357-64.Texto completo Resumo
196. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004 Mar 1;38(5):612-9.Texto completo Resumo
197. Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol. 2008 Jan;102(1):11-9.Texto completo Resumo
198. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011 Jun;5(6):e1153.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal